GT Biopharma Return On Equity vs. Current Valuation
| GTBP Stock | USD 3.53 0.15 4.08% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter (1.02) | Current Value (1.07) | Quarterly Volatility 5.89517135 |
For GT Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of GT Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well GT Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between GT Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of GT Biopharma over time as well as its relative position and ranking within its peers.
GTBP |
Is GT Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GT Biopharma. If investors know GTBP will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GT Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.01) | Return On Assets (0.54) | Return On Equity (1.05) |
The market value of GT Biopharma is measured differently than its book value, which is the value of GTBP that is recorded on the company's balance sheet. Investors also form their own opinion of GT Biopharma's value that differs from its market value or its book value, called intrinsic value, which is GT Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GT Biopharma's market value can be influenced by many factors that don't directly affect GT Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GT Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if GT Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GT Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
GT Biopharma Current Valuation vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining GT Biopharma's current stock value. Our valuation model uses many indicators to compare GT Biopharma value to that of its competitors to determine the firm's financial worth. GT Biopharma is one of the top stocks in return on equity category among related companies. It is rated as one of the top companies in current valuation category among related companies . At this time, GT Biopharma's Return On Equity is relatively stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value GT Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for GT Biopharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the GT Biopharma's earnings, one of the primary drivers of an investment's value.GTBP Current Valuation vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
GT Biopharma |
| = | -1.05 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
GT Biopharma |
| = | (4.78 M) |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
GTBP Current Valuation vs Competition
GT Biopharma is rated as one of the top companies in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 18.76 Billion. GT Biopharma has negative current valuation of (4.78 Million) contributing nothing to the industry.
GT Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in GT Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, GT Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of GT Biopharma's change in net profit over the period of time. It can combine multiple indicators of GT Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -1.1 K | -1.2 K | |
| Operating Income | -13.6 M | -14.3 M | |
| Income Before Tax | -7.6 M | -8 M | |
| Total Other Income Expense Net | 6 M | 6.3 M | |
| Net Loss | -7.6 M | -8 M | |
| Income Tax Expense | -13.6 K | -14.3 K | |
| Net Loss | -52.2 M | -54.8 M | |
| Net Loss | -10.2 M | -10.7 M | |
| Net Interest Income | 520 K | 546 K | |
| Interest Income | 741 K | 778 K | |
| Non Operating Income Net Other | 16.7 M | 14.8 M | |
| Change To Netincome | 39.6 M | 64.7 M | |
| Net Loss | (5.64) | (5.92) | |
| Income Quality | 1.17 | 1.22 | |
| Net Income Per E B T | 0.88 | 0.75 |
GTBP Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on GT Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of GT Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the GT Biopharma's important profitability drivers and their relationship over time.
Use GT Biopharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GT Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GT Biopharma will appreciate offsetting losses from the drop in the long position's value.GT Biopharma Pair Trading
GT Biopharma Pair Trading Analysis
The ability to find closely correlated positions to GT Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GT Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GT Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GT Biopharma to buy it.
The correlation of GT Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GT Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GT Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GT Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your GT Biopharma position
In addition to having GT Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run USD Crypto Fund Thematic Idea Now
USD Crypto Fund
Fund from digital currency traded on multiple global exchanges in US dollors. The USD Crypto Fund theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize USD Crypto Fund Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.Note that the GT Biopharma information on this page should be used as a complementary analysis to other GT Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for GTBP Stock analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| CEOs Directory Screen CEOs from public companies around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
To fully project GT Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of GT Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include GT Biopharma's income statement, its balance sheet, and the statement of cash flows.